title: Drug carrier nanoparticles that penetrate human chronic rhinosinusitis mucus.
abstract: No effective therapies currently exist for chronic rhinosinusitis (CRS), a persistent inflammatory condition characterized by the accumulation of highly viscoelastic mucus (CRSM) in the sinuses. Nanoparticle therapeutics offer promise for localized therapies for CRS, but must penetrate CRSM in order to avoid washout during sinus cleansing and to reach underlying epithelial cells. Prior research has not established whether nanoparticles can penetrate the tenacious CRSM barrier, or instead become trapped. Here, we first measured the diffusion rates of polystyrene nanoparticles and the same nanoparticles modified with muco-inert polyethylene glycol (PEG) coatings in fresh, minimally perturbed CRSM collected during endoscopic sinus surgery from CRS patients with and without nasal polyp. We found that uncoated polystyrene particles, previously shown to be mucoadhesive in a number of human mucus secretions, were immobilized in all CRSM samples tested. In contrast, densely PEGylated particles as large as 200 nm were able to readily penetrate all CRSM samples from patients with CRS alone, and nearly half of CRSM samples from patients with nasal polyp. Based on the mobility of different sized PEGylated particles, we estimated the average pore size of fresh CRSM to be at least 150 ± 50 nm. Guided by these studies, we formulated mucus-penetrating particles composed of poly(lactide-co-glycolide) (PLGA) and Pluronics, two materials with a long history of safety and use in humans. We showed that these biodegradable particles are capable of rapidly penetrating CRSM at average speeds up to only 20-fold slower than their theoretical speeds in water. Our findings strongly support the development of mucus-penetrating nanomedicines for the treatment of CRS.
authors.affiliation: Department of Chemical & Biomolecular Engineering, Johns Hopkins University, 3400 N. Charles Street, Baltimore, MD 21218, USA. lai@unc.edu
authors.forename: Samuel K
authors.initials: SK
authors.lastname: Lai
authors.forename: Jung Soo
authors.initials: JS
authors.lastname: Suk
authors.forename: Amanda
authors.initials: A
authors.lastname: Pace
authors.forename: Ying-Ying
authors.initials: YY
authors.lastname: Wang
authors.forename: Ming
authors.initials: M
authors.lastname: Yang
authors.forename: Olcay
authors.initials: O
authors.lastname: Mert
authors.forename: Jeane
authors.initials: J
authors.lastname: Chen
authors.forename: Jean
authors.initials: J
authors.lastname: Kim
authors.forename: Justin
authors.initials: J
authors.lastname: Hanes
mesh_terms: D004337:Drug Carriers / Q000008:administration & dosage* / Q000737:chemistry*; D006801:Humans; D066298:In Vitro Techniques; D009093:Mucus / Q000378:metabolism*; D053758:Nanoparticles / Q000008:administration & dosage* / Q000737:chemistry*; D009298:Nasal Polyps / Q000378:metabolism; D020442:Poloxamer / Q000737:chemistry; D011092:Polyethylene Glycols / Q000737:chemistry; D011098:Polyglactin 910 / Q000737:chemistry; D012852:Sinusitis / Q000378:metabolism*
chemical_list: D004337:Drug Carriers; D020442:Poloxamer; D011098:Polyglactin 910; D011092:Polyethylene Glycols